Stroke · 2026
Parent Perspectives on I-ACQUIRE Therapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yale Mara M, Hindery Kimberly A, Murray Jennifer F, Darragh Amy R, Ramey Craig T, DeLuca Stephanie C, Pauls Qi, Heathcock Jill C, Lo Warren D, Martin Renee H, Trucks Mary Rebekah, Ramey Sharon Landesman
Аннотация
BACKGROUND: Although Constraint-Induced Movement Therapy is increasingly recommended as an evidence-based, intensive treatment for children with hemiparesis, parent perspectives are lacking. I-ACQUIRE, a multicomponent form of Constraint-Induced Movement Therapy, involves substantial parent participation. Child outcomes from the United States 15-site I-ACQUIRE phase 3 clinical trial (2019-2025), partnered with a Parent Council, are presented elsewhere. Here, we examine complementary lived-experience parent data.
METHODS: All parents (167) of infants/toddlers with perinatal arterial ischemic stroke and hemiparesis consented to child random assignment to usual treatment (UT), moderate-dose I-ACQUIRE (3 h/d, 5 d/wk over 4 weeks), or high-dose I-ACQUIRE (6 h/d). Parents completed assessments about life- and therapy-related stress, treatment concerns, observations of child progress, and perceived therapy-related responsibilities.
RESULTS: Parents of children in the I-ACQUIRE moderate-dose (56) and high-dose group (58), compared with UT (53), reported lower rates of concerns or problems that therapy did not produce clear benefits (≤4% versus 18%), child-therapist interactions (≤2% versus 24%), and parent-therapist interactions (≤2% versus 6%). I-ACQUIRE versus UT parents had higher proportions of positive feelings that therapy was useful (94%-98% versus 83%); interesting (96%-98% versus 79%), important (94%-98% versus 85%), and fun (78%-84% versus 53%); and provided comforting (72%-83% versus 47%) and relaxing benefits (28%-31% versus 17%). In all groups, similar proportions reported their role was stressful (I-ACQUIRE 26%-28%, UT 32%), difficult (I-ACQUIRE 35%-48%, UT 38%), and tiring (I-ACQUIRE 48%-52%, UT 43%). General life stress scores were mostly in the moderate-range category, similar across groups.
CONCLUSIONS: Parents of I-ACQUIRE children reported higher positive feelings and notably fewer concerns about lack of benefits compared with UT. Across all groups, some parents (<52%) reported treatment-related stress, difficulty, and fatigue. These findings provide new perspectives from parents' lived experiences to help families and clinicians in treatment decision-making.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03910075.
METHODS: All parents (167) of infants/toddlers with perinatal arterial ischemic stroke and hemiparesis consented to child random assignment to usual treatment (UT), moderate-dose I-ACQUIRE (3 h/d, 5 d/wk over 4 weeks), or high-dose I-ACQUIRE (6 h/d). Parents completed assessments about life- and therapy-related stress, treatment concerns, observations of child progress, and perceived therapy-related responsibilities.
RESULTS: Parents of children in the I-ACQUIRE moderate-dose (56) and high-dose group (58), compared with UT (53), reported lower rates of concerns or problems that therapy did not produce clear benefits (≤4% versus 18%), child-therapist interactions (≤2% versus 24%), and parent-therapist interactions (≤2% versus 6%). I-ACQUIRE versus UT parents had higher proportions of positive feelings that therapy was useful (94%-98% versus 83%); interesting (96%-98% versus 79%), important (94%-98% versus 85%), and fun (78%-84% versus 53%); and provided comforting (72%-83% versus 47%) and relaxing benefits (28%-31% versus 17%). In all groups, similar proportions reported their role was stressful (I-ACQUIRE 26%-28%, UT 32%), difficult (I-ACQUIRE 35%-48%, UT 38%), and tiring (I-ACQUIRE 48%-52%, UT 43%). General life stress scores were mostly in the moderate-range category, similar across groups.
CONCLUSIONS: Parents of I-ACQUIRE children reported higher positive feelings and notably fewer concerns about lack of benefits compared with UT. Across all groups, some parents (<52%) reported treatment-related stress, difficulty, and fatigue. These findings provide new perspectives from parents' lived experiences to help families and clinicians in treatment decision-making.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03910075.